Glenmark Life Sciences’ Q2 net profit falls 20% y-o-y

Glenmark Life Sciences‘ net profit for the second quarter of fiscal year 2025 fell 20% year-on-year (YoY) to ₹95.32 Crore. This is due to the temporary closure of its Gujarat manufacturing site.

Following this development, Glenmark Life Sciences slipped as much as 10% to an intraday low of ₹936.90 on NSE.

The Mumbai-based company’s income from operations decreased by roughly 15% to ₹507 Crore in the three months ended September 30. The drop was caused mostly by the shutdown of its manufacturing site in Ankleshwar, Gujarat, which had an impact on quarterly revenue across many countries.

Glenmark Life Sciences anticipates a recovery in the second half of the fiscal year, notwithstanding the setback. As multinational pharmaceutical businesses work to lessen their dependency on China, the company continues to benefit from rising demand in important regions including the US and Europe.

With a portfolio of more than 130 active pharmaceutical ingredients (APIs) in important therapeutic areas like cardiology, oncology, and anti-infectives, Glenmark Life is still well-positioned for growth in the pharmaceutical industry.

At around 11.28 AM, Glenmark Life Sciences was trading 10% lower at ₹936.90, against the previous close of ₹1,041 on NSE. The counter touched an intraday high and low of ₹1,025, and ₹936.90, respectively.

For feedback and suggestions, write to us at editorial@iifl.com